Top

Sleep and Breathing

Published in:

01-02-2010 | Original Article

Effects of allopurinol on cardiac function and oxidant stress in chronic intermittent hypoxia

Authors: Antoinette L. Williams, Ling Chen, Steven M. Scharf

Published in: Sleep and Breathing | Issue 1/2010

Abstract

Rationale

Obstructive sleep apnea is associated with left ventricular (LV) dysfunction, oxidant stress, and chronic intermittent hypoxia (CIH). Allopurinol (ALLO) is a xanthine oxidase inhibitor that also scavenges free radicals.

Objectives

Using an animal model of CIH we hypothesized that ALLO decreases oxidant stress and cardiac injury.

Materials and methods

Rats were exposed to either CIH (nadir 4–6%, approximately once per minute) or room air (handled controls, HC) for 8 h a day for 10 days. Four treatment groups (six to ten animals per group) were studied: CIH/ALLO, CIH/placebo (PLAC), HC/ALLO, and HC/PLAC. Outcomes included myocardial lipid peroxides (LPO) for oxidant stress, fraction shortening of the LV cavity for cardiac function (LVFS) and an assay for myocyte apoptosis.

Results

LPO was lower in CIH/ALLO group compared to CIH/PLAC (179 ± 102 vs. 589 ± 68 mcg/mg protein, p < 0.05). LVFS was greater in ALLO animals than PLAC in both CIH and HC (CIH/ALLO 48.6 ± 2.3% vs. CIH/PLAC 38 ± 1.4%; HC/ALLO 64.9 ± 1.8% vs. HC/PLAC 51.5 ± 1.5%; both p < 0.05). Terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) assay showed fewer apoptotic nuclei in LV myocardium in CIH/ALLO compared to CIH/PLAC (38.0 ± 1.4 vs. 48.6 ± 2.3 positive nuclei per 2.5 mm² area, p < 0.05).

Conclusion

ALLO is associated with improvement in CIH-associated oxidant stress, myocardial dysfunction, and apoptosis in rats.

Young T, Peppard PE (2000) Epidemiological evidence for and association of sleep disordered breathing with hypertension and cardiovascular disease. In: Bradley TD, Floras JS (eds) Sleep apnea: implications in cardiovascular and cerebrovascular disease. Marcel Dekker, New York, pp 261–284

Lattimore JD, Celermajer DS, Wilcox I (2003) Obstructive sleep apnea and cardiovascular disease. J Am Coll Cardiol 41:1429–1437CrossRefPubMed

Lavie L (2005) Sleep-disordered breathing and cerebrovascular disease: a mechanistic approach. Neurol Clin 23:1059–1075CrossRefPubMed

Podszus TE, Greenberg H, Scharf SM (1993) Influence of sleep state and sleep disordered breathing on cardiovascular function. In: Sullivan CE, Saunders NA (eds) Sleep and breathing II. Marcel Dekker, New York, pp 257–310

Lavie P, Here P, Hoffstein V (2000) Obstructive sleep apnoea syndrome as a risk factor for hypertension: population study. BMJ 320:479–482CrossRefPubMed

Grote L, Hedner J, Peter JH (2000) Sleep-related breathing disorder is an independent factor for uncontrolled hypertension. J Hypertens 18:679–685CrossRefPubMed

Shahar E, Whitney CW, Redline S, Lee ET, Newman AB, Javier Nieto F, O’Connor GT, Boland LL, Schwartz JE, Samet JM, for the Sleep Heart Health Study Research group (2001) Sleep-disordered breathing and cardiovascular disease cross-sectional results of the Sleep Heart Health Study. Am J Respir Crit Care Med 163:19–25PubMed

Moore T, Rabben T, Wiklund U, Franklin KA, Eriksson P (1996) Sleep-disordered breathing in men with coronary artery disease. Chest 109:659–663CrossRef

Lavie L (2004) Sleep apnea syndrome, endothelial dysfunction, and cardiovascular morbidity. Sleep 27:1053–1055PubMed

10.

Sica AL, Greenberg HE, Ruggiero DA, Scharf SM (2000) Chronic intermittent hypoxia: a model of sympathetic activation in the rat. Resp Physiol 121:173–184CrossRef

11.

Williams A, Scharf SM (2007) Obstructive sleep apnea, cardiovascular disease, and inflammation—is NF-kB the key? Sleep Breath 11:69–76CrossRefPubMed

12.

Chen L, Einbinder E, Zhang Q, Hasday J, Balke WC, Scharf SM (2005) Oxidative stress and left ventricular function with chronic intermittent hypoxia in rats. Am J Resp Crit Care Med 172:915–920CrossRefPubMed

13.

Chen L, Zhang J, Gan TX, Chen-Izu Y, Hasday JD, Karmazyn M, Balke CW, Scharf SM (2008) Left ventricular dysfunction and associated cellular injury in rats exposed to chronic intermittent hypoxia. J Appl Physiol 104:218–223CrossRefPubMed

14.

Lavie L (2003) Obstructive sleep apnoea syndrome—an oxidative stress disorder. Sleep Med Rev 7:35–51CrossRefPubMed

15.

Lavie L, Vishnevsky A, Lavie P (2004) Evidence for lipid peroxidation in obstructive sleep apnea. Sleep 27:123–128PubMed

16.

Richter C, Gogvadze V, Laffranchi R et al (1995) Oxidants in mitochondria: from physiology to diseases. Biochim Biophys Acta 1271:67–74PubMed

17.

McCord JM (1985) Oxygen derived free radicals in postischemic tissue injury. New Engl J Med 312:159–163PubMedCrossRef

18.

Row BW, Liu R, Xu W, Lheirandish L, Gozal D (2003) Intermittent hypoxia is associated with oxidative stress and spatial learning deficits in the rat. Am J Resp Crit Care Med 167:1548–1553CrossRefPubMed

19.

Pacher P, Nivorozhkin A, Szabo C (2006) Therapeutic effects of xanthine oxidase inhibitors: renaissance half a century after the discovery of allopurinol. Pharmacol Rev 58:87–114CrossRefPubMed

20.

Biagi P, Abate L (2005) Heart failure, oxidative stress and allopurinol. Monaldi Arch Chest Dis 64:33–37PubMed

21.

Movahed A, Nairg KG, Ashavaid TF (1996) Free radical generation and the role of allopurinol as a cardioprotective agent during coronary artery bypass grafting surgery. Can J Cardiol 1996(12):138–144

22.

George J, Struthers A (2008) The role of urate and xanthine oxidase inhibitors in cardiovascular disease. Cardiovascular Therapeutics 26:59–64PubMed

23.

Kittleson M, Hare J (2005) Xanthine oxidase inhibitors: an emerging class of drugs for heart failure. Eur Heart J 26:1458–1460CrossRefPubMed

24.

Hayashi K et al (2008) Xanthine oxidase inhibition improves left ventricular dysfunction in dilated cardiomyopathic hamsters. Journal of Cardiac Failure 14:238–244CrossRefPubMed

25.

Rhoden E, Teloken C, Lucas M, Rhoden C, Mauri M, Zettler C, Bello-Klein A, Barrous E (2000) Protective effect of allopurinol in the renal ischemic-reperfusion in uninephrectomized rats. Gen Pharmacol 35:189–193PubMed

26.

Solh AA, Saliba R, Bosinski T, Grant BJ, Berbary E, Miller N (2006) Allopurinol improves endothelial dysfunction in sleep apnea: a randomized control trial. Eur Respir J 27:997–1002PubMed

27.

Hoshikawa Y, Ono S, Suzuki S et al (2001) Generation of oxidative stress contributes to the development of pulmonary hypertension induced by hypoxia. J Appl Physiol 90:1299–1306PubMed

28.

Solh A, Akinnusi M, Baddoura F, Mankowski C (2007) Endothelial Cell Apoptosis in Obstructive Sleep Apnea. American Journal of Respiratory Critical Care Medicine.

29.

Berry C and Hare J (2004) Xanthine oxidoreductase and cardiovascular disease: molecular mechanisms and pathophysiological implications. J Physiol 589–606.

30.

Landmesser U, Drexler H (2002) Allopurinol and endothelial functionin heart failure future or fantasy. Circulation 106:173–175CrossRefPubMed

31.

Doehner W etc (2002). Effects of Xanthine Oxidase Inhibititon With Allopurinol on Endothelial Dysfunction and peripheral blood flowin Hyperuricemic Patients with Chronic Heart Failure. Circulation 2619–2624.

32.

Ryter SW, Kim HP, Hoetzel A, Park JW, Nakahira K, Wang X, Choi AMK (2007) Mechanisms of cell death in oxidative stress. Antioxid Redox Signal 9:49–89CrossRefPubMed

33.

Park JB, Touyz RM, Chen X, Schiffrin EL (2002) Chronic treatment with a superoxide dismutase mimetic prevents vascular remodeling and progression of hypertension in salt-loaded stroke-prone spontaneously hypertensive rats. Am J Hypertens 15:78–84CrossRefPubMed

34.

Midaoui AE, deChamplain J (2002) Prevention of hypertension, insulin resistance, and oxidative stress by alpha-lipoic acid. Hypertension 39:303–307CrossRefPubMed

35.

Kogler H, Fraser M, McCune S, Altschuld R, Marban E (2003) Disproportionate enchancement of myocardial contractility by the xanthine oxidase inhibitor oxypurinol in failing rat myocardium. Cardiovasc Res 59:582–592CrossRefPubMed

36.

Saavedra WF, Paolocci N, St John ME, Skaf MW, Stewart GC, Xie JS, Harrison RW, Zeichner J, Mudrick D, Marban E, Kass DA, Hare JM (2002) Imbalance between xanthine oxidase and nitric oxide synthase signaling pathways underlies mechanoenergetic uncoupling in the failing heart. Circ Res 90:297–304CrossRefPubMed

37.

Stull LB, Leppo MK, Szweda L, Gao WD, Marban E (2004) Chronic treatment with allopurinol boosts survival and cardiac contractility in murine postischemic cardiomyopathy. Circ Res 95:1005–1011CrossRefPubMed

38.

Scharf SM, Williams AL, Chen L, Wu J (2008) Short term chronic intermittent hypoxia leads to cardiac dysfunction and oxidative stress. Sleep 31:A182 (abstract supplement)

Title: Effects of allopurinol on cardiac function and oxidant stress in chronic intermittent hypoxia
Authors: Antoinette L. Williams
Ling Chen
Steven M. Scharf
Publication date: 01-02-2010
Publisher: Springer-Verlag
Published in: Sleep and Breathing / Issue 1/2010
Print ISSN: 1520-9512
Electronic ISSN: 1522-1709
DOI: https://doi.org/10.1007/s11325-009-0279-x

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Rationale

Objectives

Materials and methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2010

Acoustic rhinometry in pediatric sleep apnea

Clinical perspective: monitoring sodium oxybate-treated narcolepsy patients for the development of sleep-disordered breathing

Are the adverse effects of body position in patients with obstructive sleep apnea dependent on sleep stage?

A comparison of polysomnographic variables between obese adolescents with polycystic ovarian syndrome and healthy, normal-weight and obese adolescents

Sexual dysfunction in women with obstructive sleep apnea

Prevalence and impact of sleep disorders and sleep habits in the United States

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials